(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
-4.36% $ 3.73
Live Chart Being Loaded With Signals
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector...
Stats | |
---|---|
Dzisiejszy wolumen | 15 050.00 |
Średni wolumen | 68 096.00 |
Kapitalizacja rynkowa | 132.87M |
EPS | $0 ( 2024-04-03 ) |
Następna data zysków | ( $-0.340 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.19 |
ATR14 | $0.0180 (0.48%) |
Eupraxia Pharmaceuticals Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
TCL-A.TO | 0.937 |
CFP.TO | 0.902 |
AQN.TO | 0.902 |
AW-UN.TO | 0.901 |
BLX.TO | 0.894 |
TULB.TO | 0.893 |
WTE.TO | 0.893 |
ESGF.TO | 0.89 |
NPI.TO | 0.89 |
BIP-UN.TO | 0.889 |
10 Najbardziej negatywne korelacje | |
---|---|
SUSA.TO | -0.93 |
IAF-PI.TO | -0.883 |
OBE.TO | -0.88 |
MEG.TO | -0.875 |
PEY.TO | -0.87 |
CTZ.V | -0.869 |
PKI.TO | -0.861 |
RQK.TO | -0.85 |
URB.TO | -0.843 |
VLE.TO | -0.842 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Eupraxia Pharmaceuticals Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-209 911 (0.00 %) |
EPS: | $-1.580 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-209 911 (0.00 %) |
EPS: | $-1.580 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-193 273 (0.00 %) |
EPS: | $-1.210 |
Financial Reports:
No articles found.
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej